4/A: Arbutus Biopharma CFO Receives Stock Option Grant

Tuan Nguyen, CFO of Arbutus Biopharma, was granted a stock option for 750,000 shares at an exercise price of $3.49, vesting over four years.

Summary

• Tuan Nguyen, the Chief Financial Officer of Arbutus Biopharma, received a stock option grant on March 31, 2025.
• The option is for 750,000 common shares of Arbutus Biopharma.
• The exercise price of the stock option is $3.49 per share.
• The option vests over a four-year period, with 25% vesting on the first anniversary of the grant date.
• The remaining 75% vests in substantially equal monthly installments over the subsequent three years, contingent upon continuous service.
• The expiration date of the option is March 31, 2035.
• This Form 4/A is an amendment to correct the exercise price of the stock option, which was incorrectly reported on the original Form 4 filed on March 31, 2025.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. The amendment to correct the exercise price is a neutral event.

Positives

• The stock option grant aligns the CFO's interests with those of the shareholders, incentivizing him to improve the company's performance.
• The vesting schedule encourages long-term commitment from the CFO.

Future Outlook

NA

Industry Context

Stock options are a common form of executive compensation in the biopharmaceutical industry, used to attract and retain talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology industry.
• Companies like Gilead Sciences, Amgen, and Vertex Pharmaceuticals also utilize stock options to incentivize their executives.
• The vesting schedule and exercise price are typical for such grants, designed to reward long-term value creation.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the CFO to improve company performance.
• Employees may see the grant as a sign of the company's commitment to its leadership team.

Key Dates

Keywords

stock option, Arbutus Biopharma, ABUS, CFO, Tuan Nguyen, Form 4, equity compensation, vesting